HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Executive Decisions: Kidman And Sera Labs, Walmart Health-Wellness Chief, India Industry Achievement Nod To Sabinsa Founder, More

Executive Summary

Walmart names internist and cardiologist to lead health and wellness; Rite Aid category manager receives homeopathic pharmacists’ Integrative Medicine Award; India industry lifetime achievement award for Sabinsa’s Majeed; Kidman works wth Sera Labs; and more executive decisions.

You may also be interested in...



HBW Market Executive Decisions: Sabinsa, Nutrition21, Council Of Manufacturing Association

Sabinsa founder edits selenium research book; Everwell adds Nutrition21 executives; and ACI’s Hockstad leads NAM Council of Manufacturing Associations.

HBW News: CRN Expands Staff, Sami-Sabinsa CEO Dies, GOED Database Study Published

Sami-Sabinsa announces death of CEO Nair; government affairs director, scientific/regulatory affairs manager, membership associate join CRN; and GOED launches database with more than 45,000 EPA, DHA studies.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel